ESSA Pharma Inc is a pharmaceutical company. The company is in preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs which selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
| Website: | www.essapharma.com |
| Main Phone: | +1 778 331-0962 |
| Address: | 999 West Broadway Street |
| Address 2: | Suite 720 |
| State: | BC |
| City / Town: | Vancouver |
| Country: | CAN |
| Postal Code: | V5Z 1K5 |
| Exchange: | NSC |
| CEO: | David R. Parkinson |
| Employees: | 15 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait ESSA Pharma Inc is a pharmaceutical company. The company is in preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs which selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
| Website: | www.essapharma.com |
| Main Phone: | +1 778 331-0962 |
| Address: | 999 West Broadway Street |
| Address 2: | Suite 720 |
| State: | BC |
| City / Town: | Vancouver |
| Country: | CAN |
| Postal Code: | V5Z 1K5 |
| Exchange: | NSC |
| CEO: | David R. Parkinson |
| Employees: | 15 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 2.00 | Change $ -0.14 | Change % -6.54 | Tick N/A |
| Bid 2.00 | Bid Size 500.00 | Ask 2.18 | Ask Size 100.00 |
| Open 2.15 | High 2.15 | Low 1.98 | Prev Close 2.14 |
| Last Trade | Volume 16,912 | 52 Wk Hi 4.69 | 52 Wk Low 1.87 |
| Market Cap 11.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 5,776,098.00 | EPS (TTM) N/A | PE Ratio N/A | Exchange NCM |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 14 | 14 | 160 | 14 |
| Low Target Price Estimate | 10 | 10 | 10 | 10 |
| Mean Target Price Estimate | 12 | 12 | 61.33 | 12 |
| Standard Deviation | 2.83 | 2.83 | 85.47 | 2.83 |
| Date of Most Recent Estimate | 03/26/18 | 03/26/18 | 05/01/18 | 03/26/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 119 | 2018-05-25 |
| S-8 | Securities offered to employees under employee benefit plans | 14 | 2018-05-18 |
| S-8 POS | Post-effective amendment to an S-8 filing | 5 | 2018-05-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 56 | 2018-05-15 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-05-11 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 6 | 2018-05-08 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-04-26 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 6 | 2018-04-25 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-04-24 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 4 | 2018-04-20 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
